Clinical trials: MEASLES DISEASE
Malaria
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen
This study is being done to assess the possibility of the potential integration of malaria vaccine into the EPI regimen. It will evaluate whether the malaria vaccine is safe and immunogenic in infants aged 6 to 10 weeks at first…
- Trial name
- NCT00436007
- Testing
- GSK 257049, Tritanrix™ HepB/Hib, Rouvax™
- Where
- 3 sites in Gabon, Ghana and 1 more
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00092391
- Testing
- Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live, Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
- Volunteers
- 1,997 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
The primary study objectives are: To demonstrate that a 2-dose regimen of ProQuad® manufactured with recombinant Human Albumin (rHA) administered at a 3-month interval to healthy children of 11 months of age at the time of Dose 1…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00566527
- Testing
- ProQuad® manufactured with recombinant Human Albumin (rHA)
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles
Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings
This is a phase IIb clinical trial investigating the non-inferiority of immune responses in children given two doses of measles vaccine at different timepoints.
- Trial name
- BoostMe (NCT06667206)
- Testing
- Licenced Measles-Rubella vaccine
- Where
- Uganda
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Measles, Mumps
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck \& Co., Inc.'s MMR vaccine, which is approved for…
- Conditions
- Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT01681992
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 81 sites in United States, Czechia and 5 more
- Volunteers
- 4,538 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Safety Issues, Immunogenicity
Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children
to assess safety and immunogenicity of measles-rubella (MR) routine immunization in Indonesian Children and Infants
- Trial name
- NCT03680417
- Testing
- Measles-Rubella (MR) Vaccine
- Where
- Indonesia
- Volunteers
- 590 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Diphtheria, Tetanus
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
The project goal is to conduct a randomized controlled trial (RCT) to test whether mobile phone short message system (SMS) reminders, either with or without mobile-phone based travel subsidies will improve timeliness, coverage…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- m-SIMU (NCT01878435)
- Testing
- SMS reminder, Travel subsidy, Travel subsidy 2
- Where
- Kenya
- Volunteers
- 2,018 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Encephalitis, Japanese B
Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
This study will determine whether it is safe and effective to administer Japanese encephalitis (JE) live attenuated SA 14-14-2 vaccine at the same time as measles vaccine.
- Trial name
- NCT00249769
- Testing
- Live Japanese encephalitis vaccine SA 14-14-2 (LJEV), Measles Vaccine (MV)
- Where
- Philippines
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PATH
Measles, Mumps
Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)
Primary objective: To compare if, when given concomitantly with VARIVAX® by the same route at 12-18 months of age using separate injection sites, a single dose of M-M-RTMII administered by IM route is as immunogenic as a single…
- Conditions
- Measles, Mumps, Varicella
- Trial name
- NCT00432523
- Testing
- M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®
- Where
- 2 sites in France, Germany
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Japanese Encephalitis
Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age
To facilitate introduction of live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) into the National Immunization Programme of Sri Lanka, we evaluated the safety and immunogenicity of co-administration of LJEV and…
- Trial name
- JEV03 (NCT00463684)
- Testing
- Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine, Live, attenuated measles vaccine
- Where
- 3 sites in Sri Lanka
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- PATH
Measles, Mumps
Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine
This study will evaluate the immunogenicity and safety of Beijing Tiantan's MMR vaccine in subjects 18 months of age and older. The MMR vaccine may be administered as a second dose to 4-6 year-old persons with one dose…
- Conditions
- Measles, Mumps, Rubella, Adverse Event Following Immunisation
- Trial name
- NCT03160820
- Testing
- Measles, mumps and rubella Combined Vaccine, Live
- Where
- 4 sites in China
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Measles, Mumps
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
The present study will explore the immunogenicity of AVAXIM™ 80U-Pediatric in 12-13 months Turkish children and check if the administration of the MMR trivalent vaccine on the same day but at different site will interfere on…
- Conditions
- Measles, Mumps, Rubella, Hepatitis A
- Trial name
- NCT00313950
- Testing
- Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella, Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Measles Vaccination
Predictors of Measles Vaccine Hesitancy in New York State
Under-immunization rates for childhood immunizations in the United States range from 8-20%. Previous studies have demonstrated that pediatric patients are most likely to be under-immunized for seasonal immunizations.
- Trial name
- NCT07373093
- Testing
- Survey
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Albany Medical College
Immunogenicity, Reactogenicity
Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants
Open-label, single-arm trial, Primary Objectives included: 1. To assess the immunogenicity of TrivivacTM administered in healthy infants aged between 9-14 months. 2.
- Trial name
- NCT01763268
- Testing
- Trivivac vaccine
- Where
- Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Queen Sirikit National Institute of Child Health
Rubella, Measles
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
The purpose of this study is to evaluate consistency in terms of the immune response to three different lots of GSK Biologicals' trivalent MMR vaccine manufactured to target potencies, and compare its immunogenicity to Merck \&…
- Conditions
- Rubella, Measles, Mumps
- Trial name
- NCT01702428
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 90 sites in United States, Estonia and 4 more
- Volunteers
- 5,016 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Varicella
Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine
This trial will evaluate the safety and immunogenicity of: i) measles vaccine (CAM-70) after primary dose at 6 months (MV1) and booster vaccination at 12 months (MV2); ii) a single dose of varicella vaccination at 18 months; and…
- Conditions
- Measles, Varicella, Hepatitis A
- Trial name
- MV/VV/Hep-AV (NCT03330171)
- Testing
- Measles vaccine, Hepatitis-A vaccine, Varicella vaccine
- Where
- South Africa
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
Measles-Mumps-Rubella
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
The purpose of this study is to support licensure of GSK Biologicals' MMR vaccine (Priorix®) in the US by generating immunogenicity and safety data in contrast to the US standard of care, Merck's MMR vaccine (M-M-R®II), when…
- Trial name
- NCT01621802
- Testing
- Priorix, M-M-R II, Kinrix
- Where
- 67 sites in United States, South Korea and 1 more
- Volunteers
- 4,011 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Covid19, Measles Vaccine
Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?
Mortality rates caused by SARS CoV-2 differ between countries and this difference might be explained by several reasons. Childhood vaccination rate is thought to be one of them.
- Conditions
- Covid19, Measles Vaccine, Mortality
- Trial name
- NCT04468802
- Testing
- Case fatality rate
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Immunotoxicity, Vaccine
Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live
To evaluate the immunogenicity, lot-to-lot consistency and safety of three consecutive batches of Measles, Mumps and Rubella Combined Vaccine, Live.
- Trial name
- NCT05161845
- Testing
- Measles, Mumps and Rubella Combined Vaccine, Live
- Where
- China
- Volunteers
- 1,068 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Measles, Mumps
Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00351923
- Testing
- MeMuRu-OKA (study vaccine)
- Where
- 20 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline